Relapse Predictors in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2024 Sep 14

PMID 39272634

Authors

Katarzyna Wawrzycka-Adamczyk

Mariusz Korkosz

Jacek Musial

Krzysztof Wojcik

Affiliations

Soon will be listed here.

Abstract

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of rare diseases with a chronic and relapsing course. Recent treatment guidelines offer many therapeutic options depending mainly on the type of diagnosis and disease manifestations. Areas that remain under discussion include whether all patients diagnosed with AAV belong to a homogeneous group with a similar prognosis at baseline or if the type and duration of remission-inducing treatment should depend on factors other than just diagnosis and disease severity. The aim of this review is to present the recent literature on the tools available to use while evaluating the risk of relapse in patients upon presentation as well as potential biomarkers of proceeding flare in patients upon remission.

References

Holle J, Gross W, Holl-Ulrich K, Ambrosch P, Noelle B, Both M . Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage?. Ann Rheum Dis. 2010; 69(11):1934-9. DOI: 10.1136/ard.2010.130203. View

Robson J, Grayson P, Ponte C, Suppiah R, Craven A, Judge A . 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022; 81(3):315-320. DOI: 10.1136/annrheumdis-2021-221795. View

Grayson P, Monach P, Pagnoux C, Cuthbertson D, Carette S, Hoffman G . Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford). 2014; 54(8):1351-9. PMC: 4502335. DOI: 10.1093/rheumatology/keu427. View

Gonzalez-Gay M, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J . The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum. 2003; 49(3):388-93. DOI: 10.1002/art.11115. View

Hilhorst M, Arndt F, Kemna M, Wieczorek S, Donner Y, Wilde B . HLA-DPB1 as a Risk Factor for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Cohort Study. Arthritis Rheumatol. 2016; 68(7):1721-30. DOI: 10.1002/art.39620. View

Terrier B, Darbon R, Durel C, Hachulla E, Karras A, Maillard H . French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides). Orphanet J Rare Dis. 2020; 15(Suppl 2):351. PMC: 7771069. DOI: 10.1186/s13023-020-01621-3. View

Deshayes S, Martin Silva N, Khoy K, Yameogo S, Mariotte D, Lobbedez T . Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. Rheumatology (Oxford). 2019; 58(10):1731-1739. DOI: 10.1093/rheumatology/kez016. View

Little M, Al-Ani B, Ren S, Al-Nuaimi H, Leite Jr M, Alpers C . Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS One. 2012; 7(1):e28626. PMC: 3256135. DOI: 10.1371/journal.pone.0028626. View

Stone J, Merkel P, Spiera R, Seo P, Langford C, Hoffman G . Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363(3):221-32. PMC: 3137658. DOI: 10.1056/NEJMoa0909905. View

10.

Hellmich B, Sanchez-Alamo B, Schirmer J, Berti A, Blockmans D, Cid M . EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023; 83(1):30-47. DOI: 10.1136/ard-2022-223764. View

11.

Pepper R, Draibe J, Caplin B, Fervenza F, Hoffman G, Kallenberg C . Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2016; 69(1):185-193. PMC: 5839649. DOI: 10.1002/art.39814. View

12.

Stegeman C, Tervaert J, de Jong P, Kallenberg C . Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996; 335(1):16-20. DOI: 10.1056/NEJM199607043350103. View

13.

Laudien M, Hasler R, Wohlers J, Bock J, Lipinski S, Bremer L . Molecular signatures of a disturbed nasal barrier function in the primary tissue of Wegener's granulomatosis. Mucosal Immunol. 2011; 4(5):564-73. DOI: 10.1038/mi.2011.9. View

14.

Kemna M, Plomp R, van Paassen P, Koeleman C, Jansen B, Damoiseaux J . Galactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA Associated Vasculitis. EBioMedicine. 2017; 17:108-118. PMC: 5360573. DOI: 10.1016/j.ebiom.2017.01.033. View

15.

King C, Druce K, Nightingale P, Kay E, Basu N, Salama A . Predicting relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a Systematic review and meta-analysis. Rheumatol Adv Pract. 2021; 5(3):rkab018. PMC: 8407598. DOI: 10.1093/rap/rkab018. View

16.

Puechal X, Pagnoux C, Perrodeau E, Hamidou M, Boffa J, Kyndt X . Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. Arthritis Rheumatol. 2015; 68(3):690-701. DOI: 10.1002/art.39450. View

17.

Miloslavsky E, Specks U, Merkel P, Seo P, Spiera R, Langford C . Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013; 65(9):2441-9. PMC: 4949954. DOI: 10.1002/art.38044. View

18.

von Borstel A, Land J, Abdulahad W, Rutgers A, Stegeman C, Diepstra A . CD27CD38 B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients. Front Immunol. 2019; 10:2221. PMC: 6769172. DOI: 10.3389/fimmu.2019.02221. View

19.

Berden A, Ferrario F, Hagen E, Jayne D, Jennette J, Joh K . Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010; 21(10):1628-36. DOI: 10.1681/ASN.2010050477. View

20.

Schirmer J, Wright M, Herrmann K, Laudien M, Nolle B, Reinhold-Keller E . Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis.... Arthritis Rheumatol. 2016; 68(12):2953-2963. DOI: 10.1002/art.39786. View